Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated December 11, 2025, titled "Alembic Pharmaceuticals Limited receives USFDA Final Approval for Loteprednol Etabonate and Tobramycin Ophthalmic Suspension, 0.5%/0.3%".